The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

Here is a hard truth for those of us who are care providers: Americans are unsatisfied with the country's healthcare system.

The FTC report showed that from 2017 to 2022, the three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds ...

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.

(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc ... in “excess” revenue over six years, the Federal Trade Commission said in a report on the drug middlemen.

the U.S. Federal Trade Commission said on Tuesday. From 2017 to 2022, the companies — UnitedHealth Group's UNH.N Optum, CVS Health's CVS.N CVS Caremark and Cigna's CI.N Express Scripts ...

and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) accused their pharmacy benefit manager units of imposing significant price markups on specialty ...